Mark G. Foletta Sells 2,750 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director now directly owns 56,621 shares of the company’s stock, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $81.01 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $31.76 billion, a price-to-earnings ratio of 60.46, a price-to-earnings-growth ratio of 1.73 and a beta of 1.46. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.27. The business has a 50 day simple moving average of $79.80 and a 200-day simple moving average of $79.40.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. As a group, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. The Goldman Sachs Group began coverage on DexCom in a report on Friday, May 30th. They set a “buy” rating and a $104.00 target price on the stock. Citigroup reiterated a “buy” rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Finally, Barclays raised their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.50.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of DXCM. Private Trust Co. NA lifted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the last quarter. Golden State Wealth Management LLC raised its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the 1st quarter worth approximately $27,000. Optiver Holding B.V. bought a new stake in shares of DexCom in the 4th quarter worth approximately $33,000. Finally, TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.